(News Bulletin 247) – Adaptimmune Therapeutics announced on Tuesday the signing of an agreement with GSK providing for the resumption of development and marketing rights for two of its cancer therapies based on T cells.

On the Nasdaq, the action of the biotechnology company of Philadelphia (Pennsylvania) reacted up to this news, posting a gain of nearly 8% showing a market capitalization of some 200 million dollars.

Dr. Helen Tayton-Martin, Adaptimmune’s director of development and strategy, this morning welcomed the return of the ‘Prame’ and ‘NY-ESO’ programs, which she believes will strengthen the project pipeline. of the company in the treatment of solid tumors.

The company has ambitions to develop the ‘Prame’ project in particular, while it plans to evaluate the next steps it will give to NY-ESO.

Under the terms of the agreement, Adaptimmune will receive an estimated payment and royalties of approximately £30 million for the transfer of clinical trials to NY-ESO alone.

Adaptimmune and GSK had announced the conclusion of a strategic agreement in 2014 which was followed in 2017 by the exercise by GSK of an option allowing it to develop the NY-ESO program.

Copyright (c) 2023 News Bulletin 247. All rights reserved.